Is India poised to become a mega-drug park for global supplies in 2021?

Opportunities as a reliable next-gen drug source

There are extremely compelling reasons why India is on its way to become the pharmacy of the world. In these stressing times, the country’s manufacturers and suppliers of bulk drugs and APIs have proven as major service providers. Currently, we are seeing pharmaceuticals exports rise up to USD 16.3 billion. The vaccine market is estimated to hit USD 3.44 billion by 2025. With the setting up of mega-bulk drug parks across various areas, a few service providers are on the frontlines. They are offering opportunities as the next-gen drug source.

As the need for Rivastigmine API manufacturers increase, Oceanic Pharma Chem is already busy preparing ingredients that matter to the rest of the world. This informative post highlights the global compliances and standard protocols the company adheres to which include USFDA, EU, MS, PMDA and KFDA.

Spotlight on API production

If we follow the rise of pharma industry in India, it is equally critical to know how the business model is agreeable to the world buyers. Focusing specifically on Vonoprazan API Manufacturers or even Benfotiamine API Manufacturers, the vendors who make these chief ingredients are in demand. They will eventually become the pillars of the 3 mega-drug parks which India is investing in.

 

 

A generic model ideally looks like this graph below.

API constitutes the principal ingredient required to tackle the disease it is being created for. Companies like Oceanic Pharma Chem are producing specialist materials required by bulk buyers worldwide. The active pharmaceutical ingredient is sold to formulation vendors who produce the drug. The right facility consisting of the equipment, testing, Q & A is essential to prepare the ingredient. They need approval of authorities like EU or FDA based in USA. While producing a single chemical represents a focused business strategy, it is supplemented with manufacture of affordable bulk deals to export overseas. India is now investing in nearly 13 key sectors which will help API manufacturers to get better opportunities from world markets.

What is a drug-park? How will Rotigotin Api Manufacturers benefit?

COVID-19 has opened several prospects for Indian Pharma sector. For example, about 14,000 acres in Una, Himachal Pradesh is designated as the mega drug-park. It will become the hub for API Manufacturers and bulk drug makers to expand their facilities and cater to multiple enquires for producing bulk drugs. This move is definitely boosting the creation of better active ingredients with specialty chemicals. With this Pharma industry will now play a key role in India’s economic growth. It will improve the local healthcare sector offerings while catering to demands of the world. Rotigotin Api Manufacturers are now likely to have a better base to help medical markets to rise both the urban and rural markets. With better facilities it will also be possible to get vaccines, biologics, patented and healthcare products. The response to COVID-19 by the pharma industry has been excellent and supply chains are more reliable. The request for HCQ, paracetamol, API and tablet supply from India has shot up. Local manufacturers are accommodating the demand from nearly 100 countries and at the same time doing further research and development for future medical needs.

 

Oceanic PharmaChem has been in the business of APIs and Bulk Drugs for more than 50 years. It is currently a significant supplier to multinationals worldwide and is known for its commitment to production values. The company achieves the standard requirement of all major regulatory authorities. As a reliable partner who is witnessing the changes and rise of drug park in India, it encourages the new initiative to continuously serve the global market.

" />
Home Blog Detail
  • June-4-2021

Is India poised to become a mega-drug park for global supplies in 2021?

Is India poised to become a mega-drug park for global supplies in 2021?

Opportunities as a reliable next-gen drug source

There are extremely compelling reasons why India is on its way to become the pharmacy of the world. In these stressing times, the country’s manufacturers and suppliers of bulk drugs and APIs have proven as major service providers. Currently, we are seeing pharmaceuticals exports rise up to USD 16.3 billion. The vaccine market is estimated to hit USD 3.44 billion by 2025. With the setting up of mega-bulk drug parks across various areas, a few service providers are on the frontlines. They are offering opportunities as the next-gen drug source.

As the need for Rivastigmine API manufacturers increase, Oceanic Pharma Chem is already busy preparing ingredients that matter to the rest of the world. This informative post highlights the global compliances and standard protocols the company adheres to which include USFDA, EU, MS, PMDA and KFDA.

Spotlight on API production

If we follow the rise of pharma industry in India, it is equally critical to know how the business model is agreeable to the world buyers. Focusing specifically on Vonoprazan API Manufacturers or even Benfotiamine API Manufacturers, the vendors who make these chief ingredients are in demand. They will eventually become the pillars of the 3 mega-drug parks which India is investing in.

 

 

A generic model ideally looks like this graph below.

API constitutes the principal ingredient required to tackle the disease it is being created for. Companies like Oceanic Pharma Chem are producing specialist materials required by bulk buyers worldwide. The active pharmaceutical ingredient is sold to formulation vendors who produce the drug. The right facility consisting of the equipment, testing, Q & A is essential to prepare the ingredient. They need approval of authorities like EU or FDA based in USA. While producing a single chemical represents a focused business strategy, it is supplemented with manufacture of affordable bulk deals to export overseas. India is now investing in nearly 13 key sectors which will help API manufacturers to get better opportunities from world markets.

What is a drug-park? How will Rotigotin Api Manufacturers benefit?

COVID-19 has opened several prospects for Indian Pharma sector. For example, about 14,000 acres in Una, Himachal Pradesh is designated as the mega drug-park. It will become the hub for API Manufacturers and bulk drug makers to expand their facilities and cater to multiple enquires for producing bulk drugs. This move is definitely boosting the creation of better active ingredients with specialty chemicals. With this Pharma industry will now play a key role in India’s economic growth. It will improve the local healthcare sector offerings while catering to demands of the world. Rotigotin Api Manufacturers are now likely to have a better base to help medical markets to rise both the urban and rural markets. With better facilities it will also be possible to get vaccines, biologics, patented and healthcare products. The response to COVID-19 by the pharma industry has been excellent and supply chains are more reliable. The request for HCQ, paracetamol, API and tablet supply from India has shot up. Local manufacturers are accommodating the demand from nearly 100 countries and at the same time doing further research and development for future medical needs.

 

Oceanic PharmaChem has been in the business of APIs and Bulk Drugs for more than 50 years. It is currently a significant supplier to multinationals worldwide and is known for its commitment to production values. The company achieves the standard requirement of all major regulatory authorities. As a reliable partner who is witnessing the changes and rise of drug park in India, it encourages the new initiative to continuously serve the global market.

ENQUIRE WITH US
send
If You Have Any Query than Call us on +91 (22) 4212 8666